Literature DB >> 782835

Anorectic drugs: use in general practice.

D Craddock.   

Abstract

The treatment of obesity is one of the major measures available today in the field of preventive medicine. In particular, the coronary epidemic of Western civilisation would be halted, and most cases of maturity-onset diabetes prevented, if obesity were to be treated effectively. Anorectic drugs act mainly on the satiety centre in the hypothalamus to produce anorexia. They also have various metabolic effects involving fat and carbohydrate metabolism, but many of these may be secondary to loss of weight. Most of the drugs are related directly or indirectly to amphetamine and in addition act by increasing general physical activity. Anorectic drugs tend to lose their effect after some months, and part of this reduction in effect may be due to chemical alterations produced by the drugs in the brain. All the drugs, with the exception of fenfluramine, have a stimulant effect on the central nervous system in some individuals, resulting in restlessness and nervousness, irritability and insomnia. Fenfluramine commonly produces drowsiness in normal doses, but has stimulant effects with overdosage. Dexamphetamine, phenmetrazine and benzphetamine all tend to cause euphoria and the risk of addiction is therefore considerable. Euphoria occasionally occurs with diethylpropion, phentermine and chlorphentermine, but to a much lesser extent. Side-effects also occur due to sympathetic stimulation and gastro-intestinal irritation. These side-effects may cause some individuals to stop taking the drug, but are never serious or dangerous. Drug interactions may occur with monoamine oxidase inhibitors and to a clinically unimportant extent, with antihypertensive drugs. The anorectic drugs have a very definite part to play in the treatment of obesity, mainly for those individuals who have altered their eating habits but have come to a plateau of weight which they find difficult to get below. The drugs are best given in a long-acting form and can safely be continued as long as weight loss persists, provided that the clinician exercises careful supervision. Dexamphetamine, phenmetrazine and benzphetamine should rarely be used because of the danger of addiction, and chlorphentermine is potentially hazardous for long-term use. Diethylpropion emerges as the drug of first choice, as fenfluramine has a tendency to cause depression and has a higher incidence of side-effects. Fenfluramine is mainly useful for people who are especially tense and for obese maturity-onset diabetics who have been unable to lose weight with the biguanides. Mazindol and phentermine appear to be useful as alternative drugs.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 782835     DOI: 10.2165/00003495-197611050-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  46 in total

1.  AN. 448 on critical flicker frequency and heart rate in man.

Authors:  A Hedges
Journal:  S Afr Med J       Date:  1972-02-05

2.  Fenfluramine and critical flicker frequency.

Authors:  R C Hill; P Turner
Journal:  J Pharm Pharmacol       Date:  1967-05       Impact factor: 3.765

3.  Effect of diet, sulphonylureas, and phenformin on peripheral glucose uptake in diabetes and obesity.

Authors:  W J Butterfield; M J Whichelow
Journal:  Lancet       Date:  1968-10-12       Impact factor: 79.321

4.  Effect of fenfluramine on blood-lipids in man.

Authors:  G L Pawan
Journal:  Lancet       Date:  1969-03-08       Impact factor: 79.321

5.  Fenfluramine overdosage.

Authors:  M R Fleisher; D B Campbell
Journal:  Lancet       Date:  1969-12-13       Impact factor: 79.321

6.  The effect of a low-calorie diet with and without fenfluramine on the glucose tolerance and insulin secretion of obese maturity-onset diabetics.

Authors:  J R Dykes
Journal:  Postgrad Med J       Date:  1973-05       Impact factor: 2.401

7.  A comparative trial of fenfluramine and diethylpropion inbesity.

Authors:  J T Silverstone; R M Cooper; R R Begg
Journal:  Br J Clin Pract       Date:  1970-10

8.  Effects of two slimming drugs on sleep.

Authors:  I Oswald; H S Jones; J E Mannerheim
Journal:  Br Med J       Date:  1968-03-30

9.  Hypotensive effect of fenfluramine in the treatment of obesity.

Authors: 
Journal:  Practitioner       Date:  1971-07

10.  Diethylpropion hydrochloride (Tenuate Dospan) in combination with hypotensive agents in the treatment of obesity associated with hypertension.

Authors:  Y K Seedat; J Reddy
Journal:  Curr Ther Res Clin Exp       Date:  1974-05
View more
  8 in total

1.  Successful Treatment of Binge Eating Disorder With Combination Phentermine/Topiramate Extended Release.

Authors:  Anna I Guerdjikova; Angela Fitch; Susan L McElroy
Journal:  Prim Care Companion CNS Disord       Date:  2015-04-02

Review 2.  Appetite suppressants, cardiac valve disease and combination pharmacotherapy.

Authors:  Richard B Rothman; Michael H Baumann
Journal:  Am J Ther       Date:  2009 Jul-Aug       Impact factor: 2.688

Review 3.  Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA).

Authors:  J R Docherty
Journal:  Br J Pharmacol       Date:  2008-06       Impact factor: 8.739

4.  Rate-dependent effects of monoamine releasers on intracranial self-stimulation in rats: implications for abuse liability assessment.

Authors:  Clayton T Bauer; Matthew L Banks; Bruce E Blough; S Stevens Negus
Journal:  Behav Pharmacol       Date:  2013-09       Impact factor: 2.293

5.  Drugs in the pipeline for the obesity market.

Authors:  David C Klonoff; Frank Greenway
Journal:  J Diabetes Sci Technol       Date:  2008-09

6.  Amphetamine, mazindol, and fencamfamin in narcolepsy.

Authors:  J Shindler; M Schachter; S Brincat; J D Parkes
Journal:  Br Med J (Clin Res Ed)       Date:  1985-04-20

7.  Striatal dopamine homeostasis is altered in mice following Roux-en-Y gastric bypass surgery.

Authors:  India A Reddy; David H Wasserman; Julio E Ayala; Alyssa H Hasty; Naji N Abumrad; Aurelio Galli
Journal:  ACS Chem Neurosci       Date:  2014-08-05       Impact factor: 4.418

8.  Pharmacological interventions for obesity: current and future targets.

Authors:  Miriam E Bocarsly
Journal:  Curr Addict Rep       Date:  2018-05-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.